Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS - Institutional Research Information System IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.
IRInSubria - Institutional Repository Insubria IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.
Background: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national, and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors. Methods: Using data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described. Results: In 2019, there were a total of 262 million [95% uncertainty interval (UI): 224–309 million] cases of asthma and 171 million [95% UI: 165–178 million] total cases of AD globally; age-standardized prevalence rates were 3416 [95% UI: 2899–4066] and 2277 [95% UI: 2192–2369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: −27.2 to −20.8] decrease for asthma and a 4.3% [95% UI: 3.8–4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5–9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14–5.60 million] asthma DALYs and 75,377 [95% UI: 40,615–122,841] asthma deaths. Conclusions: Asthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age-standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis, and treatment.
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
Shin Y. H.;Hwang J.;Kwon R.;Lee S. W.;Kim M. S.;Shin Y. H.;Hwang J.;Kwon R.;Lee S. W.;Kim M. S.;Abate Y. H.;Abbasi-Kangevari M.;Abbasi-Kangevari Z.;Abdelmasseh M.;Abdulah D. M.;Aboagye R. G.;Abolhassani H.;Abrams E. M.;Abtew Y. D.;Abu-Gharbieh E.;Adane D. E. A.;Adane T. D.;Addo I. Y.;Adha R.;Adibi A.;Adnani Q. E. S.;Agrawal A.;Ahmad S.;Ahmadi A.;Ahmed A.;Ahmed A.;Al-Azzam S.;Alhalaiqa F. A. N.;Alif S. M.;Alipour V.;Altaany Z.;Altirkawi K. A.;Alvis-Guzman N.;Aly H.;Ansar A.;Arulappan J.;Asghari-Jafarabadi M.;Ashraf T.;Athari S. S.;Atlaw D.;Aujayeb A.;Azadnajafabad S.;Babaei M.;Babamohamadi H.;Badawi A.;Baghcheghi N.;Bagherieh S.;Bajbouj K.;Banach M.;Bardhan M.;Barone-Adesi F.;Barrow A.;Bashiri A.;Bayileyegn N. S.;Bensenor I. M.;Berhie A. Y.;Beyene K. A.;Bhagavathula A. S.;Bhardwaj P.;Bhat A. N.;Bhojaraja V. S.;Bijani A.;Bikov A.;Cai J.;Camargos P.;Car J.;Carr S.;Carugno A.;Chakraborty P. A.;Chan J. S. K.;Charalampous P.;Chashmyazdan M.;Chattu V. K.;Chowdhury M. A. K.;Chu D. -T.;Corso B.;Cruz-Martins N.;Dadras O.;Dai X.;Damiani G.;Dandona L.;Dandona R.;Demeke D.;Demisse B.;Diaz D.;Diress M.;Dongarwar D.;Ekholuenetale M.;Ekundayo T. C.;Elhadi M.;Elmeligy O. A. A.;Esubalew H.;Etaee F.;Etemadimanesh A.;Fagbamigbe A. F.;Fakhradiyev I. R.;Fatehizadeh A.;Fatima S. A. F.;Feng X.;Fereidouni M.;Ferreira N.;Fetensa G.;Fischer F.;Foroutan M.;Fukumoto T.;Gaipov A.;Gela Y. Y.;Obsa A. G.;Ghadirian F.;Ghamari S. -H.;Ghozy S.;Gillum R. F.;Gizaw A. T.;Gizaw A. B. A. B.;Goldust M.;Golechha M.;Goleij P.;Gupta S.;Gupta V. K.;Haj-Mirzaian A.;Halwani R.;Hamidi S.;Hannan M. A.;Hasaballah A. I.;Hasani H.;Hashi A.;Hassen M. B.;Heibati B.;Heidari G.;Heidari M.;Heidari-Foroozan M.;Holla R.;Horita N.;Hossain M. S.;Hussain S.;Hwang B. -F.;Ilic I. M.;Ilic M. D.;Irilouzadian R.;Ismail N. E.;Ispayeva Z. B. I. Z. B.;Iwu C. C. D.;Linda Merin J.;Jajarmi M.;Jamshidi E.;Janodia M. D.;Jayaram S.;Jebai R.;Jonas J. B.;Joseph N.;Kaambwa B.;Kabir Z.;Kaliyadan F.;Kandel H.;Kantar R. S.;Karaye I. M.;Karimi H.;Kaur H.;Keikavoosi-Arani L.;Keykhaei M.;Khader Y. S.;Khajuria H.;Khan I. A.;Khan M.;Khan M. A. B.;Khanal S.;Khatatbeh M. M.;Khubchandani J.;Kibret B. G.;Kisa A.;Kisa S.;Kolkhir P.;Kompani F.;Koohestani H. R.;Korzh O.;Koul P. A.;Koyanagi A.;Krishan K.;Kuehni C. E.;Kumar G. A.;Kurmi O. P.;Kutikuppala L. V. S.;Kuttikkattu A.;Lam J.;Larijani B.;Latief K.;Lauriola P.;Le T. T. T.;Lee Y. H.;Lenzi J.;Li M. -C.;Li S.;Ligade V. S.;Lim S. S.;Liu W.;Liu X.;Lo C. -H.;Lopes G.;Mahalingam S.;Maharaj S. B.;Mahmoud M. A.;Majeed A.;Malekpour M. -R.;Malik A. A.;Mallhi T. H.;Malta D. C.;Mamun A. A.;Masoumi S. Z.;Maugeri A.;Medina J. R. C.;Menezes R. G.;Mensah G. A.;Mentis A. -F. A.;Mestrovic T.;Michalek I. M.;Minh L. H. N.;Mirrakhimov E. M.;Misganaw A.;Mishra M.;Mohammed S.;Mokdad A. H.;Momtazmanesh S.;Monasta L.;Moniruzzaman M.;Mulugeta T.;Munblit D.;Murillo-Zamora E.;Mustafa G.;Nair T. S.;Nangia V.;Swamy S. N.;Nassereldine H.;Natto Z. S.;Nayak B. P.;Nazari J.;Ng T. P.;Nguyen D. H.;Nguyen V. T.;Niazi R. K.;Nouraei H.;Nzoputam O. J.;Oancea B.;Obaidur R. M.;Okati-Aliabad H.;Okonji O. C.;Okwute P. G.;Olagunju A. T.;Olufadewa I. I.;Orru H.;Mahesh P. A.;Padubidri J. R.;Pandey A.;Pardhan S.;Park E. -K.;Patel J.;Patil S.;Patthipati V. S.;Paudel U.;Pereira M.;Pereira R. B.;Petcu I. -R.;Podder I.;Podder V.;Mohammad A. P.;Qattea I.;Rabiee N.;Rahimi M.;Rahman M.;Rahman M. A.;Rahmani A. M.;Rahmani S.;Rahmanian V.;Rajput P.;Ram P.;Ramasubramani P.;Rao I. R.;Rashid A. M.;Ratan Z. A.;Ravikumar N.;Rawaf S.;Rawal L.;Redwan E. M. M.;Regmi A. R.;Rezaei N.;Rezaei N.;Rezaei N.;Rezaei S.;Rezaeian M.;Rodriguez J. A. B.;Roever L.;Romero-Rodriguez E.;Ronfani L.;Saad A. M. A.;Saddik B.;Saeed U.;Sagoe D.;Sharif-Askari F. S.;Sahebkar A.;Sahoo H.;Sajid M. R.;Sakshaug J. W.;Salahi S.;Salehi S.;Samy A. M.;Santric-Milicevic M. M.;Sarasmita M. A.;Sarkhosh M.;Saya G. K.;Senthilkumaran S.;Shah H.;Shaikh M. A.;Shanawaz M.;Sheikh A.;Shekhar S.;Shigematsu M.;Shobeiri P.;Shorofi S. A.;Sibhat M. M.;Simpson C. R.;Singh J. A.;Singh P.;Singh S.;Singh V.;Siraj M. S.;Skryabina A. A.;Solomon Y.;Song S.;Soshnikov S.;Soyiri I. N.;Steiropoulos P.;Szeto M. D.;Talaat I. M.;Tamuzi J. J. L. L.;Tan K. -K.;Tat N. Y.;Temsah M. -H.;Terefa D. R.;Tesler R.;Thangaraju P.;Ticoalu J. H. V.;Tillawi T.;Tran M. T. N.;Tusa B. S.;Ullah I.;Ullah S.;Ullah S.;Upadhyay E.;Vahabi S. M.;van Boven J. F. M.;Vasankari T. J.;Verras G. -I.;Vieira R. J.;Violante F. S.;Vos T.;Westerman R.;Wickramasinghe N. D.;Williams H. C.;Yada D. Y.;Yismaw Y.;Yonemoto N.;Yu C.;Yunusa I.;Zahir M.;Zar H. J.;Zare I.;Zastrozhin M. S.;Zeineddine M. A.;Zenebe G. A.;Zhang Z. -J.;Zhao H.;Zoladl M.;Shin J. I.;Yon D. K.;Shin J. I.;Yon D. K.
2023-01-01
Abstract
Background: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national, and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors. Methods: Using data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described. Results: In 2019, there were a total of 262 million [95% uncertainty interval (UI): 224–309 million] cases of asthma and 171 million [95% UI: 165–178 million] total cases of AD globally; age-standardized prevalence rates were 3416 [95% UI: 2899–4066] and 2277 [95% UI: 2192–2369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: −27.2 to −20.8] decrease for asthma and a 4.3% [95% UI: 3.8–4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5–9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14–5.60 million] asthma DALYs and 75,377 [95% UI: 40,615–122,841] asthma deaths. Conclusions: Asthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age-standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis, and treatment.
asthma; atopic dermatitis; disability-adjusted life years; eczema; epidemiology; global burden; mortality
Shin, Y. H.; Hwang, J.; Kwon, R.; Lee, S. W.; Kim, M. S.; Shin, Y. H.; Hwang, J.; Kwon, R.; Lee, S. W.; Kim, M. S.; Abate, Y. H.; Abbasi-Kangevari, M....espandi
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2174654
Attenzione
L'Ateneo sottopone a validazione solo i file PDF allegati
Citazioni
ND
53
41
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.